Wedbush Expects Higher Earnings for Tango Therapeutics

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities research analysts at Wedbush boosted their FY2025 EPS estimates for shares of Tango Therapeutics in a research note issued to investors on Tuesday, November 4th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.86) per share for the year, up from their prior estimate of ($1.35). The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Wedbush also issued estimates for Tango Therapeutics’ Q4 2025 earnings at ($0.28) EPS, Q1 2026 earnings at ($0.28) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($0.99) EPS and FY2028 earnings at ($0.07) EPS.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.12. The business had revenue of $53.81 million during the quarter, compared to the consensus estimate of $41.35 million. Tango Therapeutics had a negative return on equity of 60.80% and a negative net margin of 151.15%.

A number of other equities research analysts also recently weighed in on TNGX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, October 8th. Piper Sandler began coverage on shares of Tango Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $11.00 price objective for the company. Guggenheim boosted their target price on shares of Tango Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, October 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a report on Monday, October 27th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Tango Therapeutics Stock Up 6.7%

Shares of NASDAQ TNGX opened at $8.01 on Friday. The stock’s 50 day moving average price is $7.69 and its two-hundred day moving average price is $5.59. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $9.70. The stock has a market capitalization of $1.08 billion, a P/E ratio of -8.61 and a beta of 1.66.

Insider Buying and Selling

In other Tango Therapeutics news, major shareholder Rock Ventures Iv L.P. Third sold 1,100,000 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $7.01, for a total value of $7,711,000.00. Following the sale, the insider directly owned 15,759,075 shares of the company’s stock, valued at $110,471,115.75. This trade represents a 6.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders sold 3,472,501 shares of company stock worth $26,350,320. 7.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tango Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. bought a new position in shares of Tango Therapeutics during the second quarter worth about $30,235,000. Commodore Capital LP bought a new stake in Tango Therapeutics in the 2nd quarter valued at about $7,680,000. Soleus Capital Management L.P. acquired a new position in Tango Therapeutics during the 2nd quarter valued at about $3,738,000. Candriam S.C.A. bought a new position in Tango Therapeutics in the 2nd quarter worth about $3,629,000. Finally, Vivo Capital LLC acquired a new stake in shares of Tango Therapeutics in the second quarter valued at approximately $3,072,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.